Literature DB >> 33020155

Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Staphylococcus aureus Infection: a Novel Combination Therapy.

George Sakoulas1.   

Abstract

Given that it is unlikely that randomized clinical trials will yield answers for treating the most challenging bacteremic infections caused by methicillin-resistant Staphylococcus aureus, clinicians, microbiologists, and pharmacists will have to cooperate to discover novel ways to select successful individualized antimicrobial therapy for these patients. An example of such a strategy was demonstrated in the identification and utilization of imipenem/cilastatin plus fosfomycin to treat a particularly recalcitrant MRSA bacteremia and spinal abscess.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  MRSA; antimicrobial combinations; bacteremia

Mesh：

Substances：

Year:  2020        PMID： 33020155      PMCID： PMC7927839          DOI： 10.1128/AAC.02039-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  José M Miró; José M Entenza; Ana Del Río; Maria Velasco; Ximena Castañeda; Cristina Garcia de la Mària; Marlyse Giddey; Yolanda Armero; Juan M Pericàs; Carlos Cervera; Carlos A Mestres; Manuel Almela; Carlos Falces; Francesc Marco; Philippe Moreillon; Asuncion Moreno
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.

Authors:  Aki Yoneda; Robert Thänert; Carey-Ann D Burnham; Gautam Dantas
Journal:  Int J Antimicrob Agents       Date:  2019-12-20       Impact factor: 5.283

3.  Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures.

Authors:  Jacob M Wozniak; Robert H Mills; Joshua Olson; J R Caldera; Gregory D Sepich-Poore; Marvic Carrillo-Terrazas; Chih-Ming Tsai; Fernando Vargas; Rob Knight; Pieter C Dorrestein; George Y Liu; Victor Nizet; George Sakoulas; Warren Rose; David J Gonzalez
Journal:  Cell       Date:  2020-09-03       Impact factor: 41.582

4.  Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.

Authors:  Wessam Abdelhady; Arnold S Bayer; Rachelle Gonzales; Liang Li; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Authors:  George Sakoulas; Jeff Alder; Claudie Thauvin-Eliopoulos; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

Authors:  Kimberly C Claeys; Jordan R Smith; Anthony M Casapao; Ryan P Mynatt; Lisa Avery; Anjali Shroff; Deborah Yamamura; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

7.  Endocarditis associated with vertebral osteomyelitis and septic arthritis of the axial skeleton.

Authors:  Oscar Murillo; Imma Grau; Joan Gomez-Junyent; Celina Cabrera; Alba Ribera; Fe Tubau; Carmen Peña; Javier Ariza; Roman Pallares
Journal:  Infection       Date:  2018-02-02       Impact factor: 3.553

8.  Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.

Authors:  Steven Y C Tong; David C Lye; Dafna Yahav; Archana Sud; J Owen Robinson; Jane Nelson; Sophia Archuleta; Matthew A Roberts; Alan Cass; David L Paterson; Hong Foo; Mical Paul; Stephen D Guy; Adrian R Tramontana; Genevieve B Walls; Stephen McBride; Narin Bak; Niladri Ghosh; Benjamin A Rogers; Anna P Ralph; Jane Davies; Patricia E Ferguson; Ravindra Dotel; Genevieve L McKew; Timothy J Gray; Natasha E Holmes; Simon Smith; Morgyn S Warner; Shirin Kalimuddin; Barnaby E Young; Naomi Runnegar; David N Andresen; Nicholas A Anagnostou; Sandra A Johnson; Mark D Chatfield; Allen C Cheng; Vance G Fowler; Benjamin P Howden; Niamh Meagher; David J Price; Sebastiaan J van Hal; Matthew V N O'Sullivan; Joshua S Davis
Journal:  JAMA       Date:  2020-02-11       Impact factor: 56.272

9.  Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.

Authors:  Nagendra N Mishra; Soo-Jin Yang; Liang Chen; Claudette Muller; Azzam Saleh-Mghir; Sebastian Kuhn; Andreas Peschel; Michael R Yeaman; Cynthia C Nast; Barry N Kreiswirth; Anne-Claude Crémieux; Arnold S Bayer
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Matthew Geriak; Fadi Haddad; Khulood Rizvi; Warren Rose; Ravina Kullar; Kerry LaPlante; Marie Yu; Logan Vasina; Krista Ouellette; Marcus Zervos; Victor Nizet; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.